The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC (uHCC) and of Its Treatment with Sorafenib (GIDEON): Differences in AE reporting across physician specialties.
Alan Paul Venook
Consultant or Advisory Role - Abbott Laboratories (U); Bristol-Myers Squibb (U); Chugai Pharma (U)
Research Funding - Bayer; Onyx
Riccardo Lencioni
Honoraria - Bayer
Jorge A. Marrero
Honoraria - Bayer; Onyx
Research Funding - Bayer
Masatoshi Kudo
No relevant relationships to disclose
Keiko Nakajima
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Sheng-Long Ye
No relevant relationships to disclose
Frank Cihon
Employment or Leadership Position - Bayer